v3.26.3
Royalty Obligation (Details) - USD ($)
$ in Thousands
1 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Royalty Obligation      
Amount of upfront cash payment received     $ 75,000
Royalty Purchase Agreement [Member]      
Royalty Obligation      
Amount of upfront cash payment received $ 75,000 $ 75,000  
Percentage of royalty on net sales 5.50%    
Percentage of royalty on net sales by licensees 5.50%    
Percentage of royalty on income earned from licensees 25.00%    
Percentage of royalty on non-royalty income earned from licensees 25.00%    
Additional payment $ 225,000   225,000
Issuance costs 3,700 $ 3,691  
Royalty Purchase Agreement [Member] | Zenas' INDIGO Phase 3 Trial      
Royalty Obligation      
Additional payment 75,000   75,000
Royalty Purchase Agreement [Member] | FDA approval for IgG4-Related Disease      
Royalty Obligation      
Additional payment 75,000   75,000
Royalty Purchase Agreement [Member] | FDA for the treatment of systemic lupus erythematosus      
Royalty Obligation      
Additional payment $ 75,000   $ 75,000